Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. (NASDAQ: AIMD) is a diversified healthcare company headquartered in San Diego, California, specializing in developing innovative medical technologies for point-of-care testing (POCT), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's flagship product is VELDONA®, a low-dose oral interferon-alpha formulation aimed at enhancing immune responses against a range of diseases. Ainos' VELDONA® has shown promise in treating human disease indications such as influenza, hepatitis C, thrombocytopenia, as well as HIV-related oral warts and Behçet's disease, both of which have received Orphan Drug Designation by the U.S. FDA.
Ainos recently announced the completion of manufacturing a GMP Clinical Batch of VELDONA® in collaboration with its contract manufacturer, Swiss Pharmaceutical Co., Ltd. (Taiwan). This milestone validates Ainos' capabilities in delivering high-quality, cost-effective therapeutics and advances the company's key programs.
In addition to human therapeutics, Ainos is making strides in animal health. The company has initiated clinical trials for a new VELDONA®-based drug aimed at treating feline chronic gingivostomatitis, a serious and chronic painful oral disease. This study builds upon VELDONA®'s extensive history in animal health, demonstrating its therapeutic potential across various animal species.
Ainos is also pioneering AI-powered POCTs through its AI Nose technology platform. The company's lead POCT candidate, Ainos Flora, is designed to be a telehealth-friendly solution for women's health and common sexually transmitted infections (STIs). Furthermore, Ainos has initiated a co-development program with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to create a volatile organic compound (VOC) sensing platform. This technology aims to revolutionize applications in telehealth, automotive, industrial, and environmental safety, expanding Ainos' market reach.
Financially, Ainos has secured significant growth capital, including a $9 million convertible note from an existing shareholder. This funding will propel the company's initiatives in scaling up VELDONA® and advancing its AI Nose technology.
With nearly four decades of dedication to healthcare innovation, Ainos continues to push the boundaries of medical science, striving to deliver effective, safe, and high-quality treatments for both humans and animals. Investors and stakeholders are encouraged to follow Ainos on social media platforms like X (formerly Twitter) and LinkedIn for the latest updates and developments.
Ainos (NASDAQ:AIMD) has shared its achievements and future plans in a shareholder letter. The company is developing AI Nose technology through Smell ID, achieving 80% accuracy in VOC detection platform with plans for mass production in H1 2025. Their Ainos Flora device for women's health achieved up to 94% accuracy in clinical trials, with second-generation studies planned for H1 2025.
The company's VELDONA low-dose interferon therapy is advancing with clinical trials for Sjögren's Syndrome and HIV-related oral warts scheduled to begin in H1 2025. A strategic partnership with Taiwan Tanabe Seiyaku Co. will support VELDONA's manufacturing and commercialization. The company also plans to complete veterinary trials for feline chronic gingivostomatitis by H1 2025.
Ainos (NASDAQ:AIMD) outlines its achievements and future plans in AI-powered healthcare technology. The company is developing Smell ID, an AI-powered smell detection technology, and advancing VELDONA®, a low-dose interferon therapeutic. Key developments include:
- The Ainos Flora device for STI testing achieved 94% accuracy in clinical trials, with second-generation studies planned for H1 2025
- VOC detection platform reached 80% accuracy through collaborations with Nisshinbo Micro Devices and Itochu Techno-Solutions
- Clinical trials for VELDONA® targeting Sjögren's Syndrome and HIV-related oral warts are set to begin in H1 2025
- Strategic partnership with Taiwan Tanabe Seiyaku for VELDONA® manufacturing and commercialization
Ainos (NASDAQ:AIMD), a healthcare company specializing in AI-driven point-of-care testing and low-dose interferon therapeutics, has announced its participation in the Webull Corporate Connect Service (CCS). This strategic move aims to enhance investor engagement and transparency through real-time communication with shareholders.
Through the CCS platform, Ainos will showcase corporate milestones, strategic initiatives, and financial results to the investment community. The company's Chairman and CEO, Chun-Hsien Tsai, emphasized that this integration aligns with their commitment to transparent investor communication and will help drive long-term shareholder value.
Ainos (NASDAQ:AIMD) has formed a strategic partnership with Taiwan Tanabe Seiyaku, a Mitsubishi Tanabe Pharma subsidiary, for manufacturing and marketing VELDONA® in Taiwan. The partnership focuses on advancing VELDONA®, a therapeutic candidate for primary Sjögren's syndrome.
The collaboration leverages Taiwan Tanabe Seiyaku's PIC/S GMP-certified facility and expertise in drug manufacturing and market promotion. A clinical study of VELDONA® has received Institutional Review Board approval from Shuang Ho Hospital, with site initiation planned for April 2025 and completion expected in December 2026. Previous U.S. Phase 3 studies showed VELDONA® benefits in improving oral dryness and salivary function for Sjögren's syndrome, an autoimmune disease affecting 0.1-1.0% of the global population.
Ainos (NASDAQ: AIMD) has signed a strategic Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku, a subsidiary of Mitsubishi Tanabe Pharma , to advance the manufacturing and Taiwan market promotion of VELDONA®, their Sjögren's syndrome treatment drug. The partnership leverages Taiwan Tanabe Seiyaku's pharmaceutical development and manufacturing expertise. VELDONA®, a low-dose oral interferon-alpha, has shown promising results in clinical trials, demonstrating significant symptom alleviation and disease progression control. The collaboration aims to accelerate VELDONA®'s global market introduction, targeting the growing Sjögren's syndrome market projected to reach billions in the next five years.
Water Tower Research has published a report highlighting Ainos (NASDAQ:AIMD) receiving IRB approval from Shuang Ho Hospital for its VELDONA clinical study in primary Sjogren's syndrome. The trial is expected to begin around April 2025 after TFDA approval, with completion targeted for December 2026. The study will enroll 24 patients over 24-48 weeks to evaluate VELDONA's efficacy in improving salivary flow. Previous U.S. Phase 3 studies showed positive results. The company recently secured exclusive licenses to 28 patent assets for AI Nose VOC sensing, POCT, and other technologies. Ainos maintains sufficient cash to support operations through 2H25.
Ainos (NASDAQ:AIMD) has received IRB approval from Shuang Ho Hospital for its clinical trial of VELDONA® in treating Sjögren's syndrome. The company plans to commence a site initiation visit around April 2025, pending regulatory approvals. The study will recruit 24 patients for a 24- to 48-week treatment period. Previous U.S. clinical trials, including three Phase 3 studies, demonstrated VELDONA® significantly increases unstimulated whole salivary flow. The trial's primary endpoint is to evaluate VELDONA®'s efficacy in improving salivary flow and alleviating dryness symptoms. Patient recruitment will begin in May 2025, with study completion expected by December 2026.
Ainos (NASDAQ: AIMD) has filed complaints with NASDAQ MarketWatch and the SEC regarding suspicious trading activities in its common stock, particularly concerning large-volume sell orders. The healthcare company, which specializes in AI-powered point-of-care testing and interferon therapeutics, suspects potential regulatory violations and has requested thorough investigation to protect stockholder interests. While regulatory bodies won't confirm any investigation details, Ainos maintains its commitment to market transparency and investor protection.
Ainos (NASDAQ:AIMD) reported Q3 2024 financial results with zero revenue compared to $24,489 in Q3 2023. The company reported a net loss of $3.7M, up from $3.0M in Q3 2023. Operating expenses increased to $3.0M from $2.6M, primarily due to higher R&D investments. Cash position strengthened to $5.2M as of September 30, 2024.
Key developments include securing multi-regional patent assets for AI Nose technology, expanding VELDONA® patent portfolio for coronavirus treatments, and progressing clinical trials for Sjögren's syndrome and HIV-related oral warts. The AI Nose platform achieved 79% accuracy in detecting VOCs in semiconductor factories.
Ainos (NASDAQ:AIMD) has secured exclusive licensing rights for 28 multi-regional patent assets from strategic shareholder Taiwan Carbon Nano Technology (TCNT). The patents cover AI Nose gas sensing technology and a breakthrough nitrogen-oxygen separation technology for medical applications. The new separation technology achieves over 99% purity while using one-third of the energy compared to conventional methods, offering significant cost reduction and environmental benefits.
The patent portfolio spans multiple regions including China, Japan, Korea, Taiwan, Germany, the EU, and the US. The agreement grants Ainos exclusive sales rights for the medical-grade nitrogen-oxygen separation technology, positioning the company for expansion in the advanced medical equipment market.
FAQ
What is the current stock price of Ainos (AIMD)?
What is the market cap of Ainos (AIMD)?
What does Ainos, Inc. specialize in?
What is VELDONA®?
What recent milestones has Ainos achieved?
What are Ainos' key products?
Who are Ainos' strategic partners?
What financial steps has Ainos recently taken?
What is the AI Nose platform?
What is Ainos Flora?
What is the significance of VELDONA® in animal health?
How can investors stay updated on Ainos' developments?
